GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
Novo-nordisk a/s stock price returns to the starting point of the year! Sales of weight loss medication fall short of expectations, scaring off investors.
①Danish pharmaceutical company novo-nordisk a/s saw its stock price drop by over 40% from the year's high due to intensified competition in the weight loss drug market, supply restrictions, and financial reports falling below expectations; ② Novo Nordisk's CFO admitted that next year's sales growth rate may be in the tens of percent, significantly lagging behind market expectations; ③ Analysts believe that the current excessive selling sentiment towards weight loss drugs, the company still has high investment value.
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
CDC Warns Against a Spike in COVID, Flu Cases
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly in Pact With Chinese Biotech for Novel Weight Loss Therapy
Novo Semaglutide Data in MASH Could Negatively Impact Madrigal's Rezdiffra
Methods : and yet it's red!
Stock_Drift OP Methods : Red is making its rounds this morning, I’ll agree with that.
Methods Stock_Drift OP : No this is always red.. 24.5 seems to be strong support though